• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Florida Cancer Specialists' Medical Oncologists Co-Author Analysis of Umbralisib in Lymphoid Malignancies

Article

Three medical oncologists at Florida Cancer Specialists & Research Institute co-author a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies.

Fort Myers, FL – October 14, 2021–Florida Cancer Specialists & Research Institute (FCS) director of Clinical Research, Gustavo Fonseca, MD, FACP, director of Drug Development, Manish Patel, MD, and James Reeves, MD, a member of the FCS clinical research team, participated in a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies.

The study, “Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies,” was recently published online in Blood Advances.

Low rates of immune-mediated toxicities were observed with umbralisib and no cumulative toxicities were reported. The analysis concluded, “The favorable long-term tolerability profile and low rates of immune-mediated toxicities support the potential use of umbralisib for the benefit of a broad population of patients with lymphoid malignancies.”

Learn more.

Related Videos
Julie Patterson, PharmD, PhD
Neil Goldfarb, CEO, Greater Philadelphia Business Coalition on Health
Screenshot of Fran Gregory, PharmD, MBA, during a video interview
Yael Mauer, MD, MPH
Pregnant Patient | image credit: pressmaster - stock.adobe.com
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Robert Zimmerman, MD
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.